Corinne Hanotin

8.0k total citations · 2 hit papers
34 papers, 2.4k citations indexed

About

Corinne Hanotin is a scholar working on Surgery, Pharmacology and Economics and Econometrics. According to data from OpenAlex, Corinne Hanotin has authored 34 papers receiving a total of 2.4k indexed citations (citations by other indexed papers that have themselves been cited), including 25 papers in Surgery, 10 papers in Pharmacology and 9 papers in Economics and Econometrics. Recurrent topics in Corinne Hanotin's work include Lipoproteins and Cardiovascular Health (24 papers), Pharmacology and Obesity Treatment (6 papers) and Health Systems, Economic Evaluations, Quality of Life (6 papers). Corinne Hanotin is often cited by papers focused on Lipoproteins and Cardiovascular Health (24 papers), Pharmacology and Obesity Treatment (6 papers) and Health Systems, Economic Evaluations, Quality of Life (6 papers). Corinne Hanotin collaborates with scholars based in France, United States and Canada. Corinne Hanotin's co-authors include James M. McKenney, Evan A. Stein, Eli M. Roth, Dean J. Kereiakes, Michael J. Koren, Gaëlle Asset, Florence Thomas, Olivier Ziegler, E. Leutenegger and P Vague and has published in prestigious journals such as New England Journal of Medicine, Circulation and Journal of the American College of Cardiology.

In The Last Decade

Corinne Hanotin

34 papers receiving 2.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Safety and Efficacy of a Monoclonal Antibody to Proprotein Convertase Subtilisin/Kexin Type 9 Serine Protease, SAR236553/REGN727, in Patients With Primary Hypercholesterolemia Receiving Ongoing Stable Atorvastatin Therapy

2012 416 citations James M. McKenney, Michael J. Koren et al. Journal of the American College of Cardiology profile →
Atorvastatin with or without an Antibody to PCSK9 in Primary Hypercholesterolemia

2012 383 citations Eli M. Roth, James M. McKenney et al. New England Journal of Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Corinne Hanotin France	18	1.7k	673	586	552	308	34	2.4k
Barry Gumbiner United States	25	1.3k 0.8×	301 0.4×	1.1k 2.0×	177 0.3×	266 0.9×	51	2.7k
Teik Chye Ooi Canada	27	1.2k 0.7×	189 0.3×	1.0k 1.7×	109 0.2×	633 2.1×	79	2.4k
Stephen Donahue United States	14	583 0.4×	281 0.4×	166 0.3×	65 0.1×	118 0.4×	31	1.1k
Michael Stepanavage United States	11	905 0.5×	167 0.2×	540 0.9×	50 0.1×	242 0.8×	16	1.3k
Thomas Littlejohn United States	22	392 0.2×	82 0.1×	601 1.0×	222 0.4×	607 2.0×	43	1.4k
Kathryn A. Krueger United States	17	568 0.3×	86 0.1×	574 1.0×	55 0.1×	174 0.6×	29	1.7k
Steven Ketchum United States	10	1.2k 0.7×	156 0.2×	865 1.5×	53 0.1×	715 2.3×	26	2.5k
Amar A Sethi Denmark	20	833 0.5×	79 0.1×	950 1.6×	85 0.2×	550 1.8×	26	1.7k
Athanasios G. Kontopoulos Greece	16	930 0.6×	243 0.4×	471 0.8×	53 0.1×	626 2.0×	26	1.4k
Muhammad Yasin United States	5	1.1k 0.7×	40 0.1×	783 1.3×	187 0.3×	392 1.3×	13	1.7k

Countries citing papers authored by Corinne Hanotin

Since Specialization

Citations

This map shows the geographic impact of Corinne Hanotin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Corinne Hanotin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Corinne Hanotin more than expected).

Fields of papers citing papers by Corinne Hanotin

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Corinne Hanotin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Corinne Hanotin. The network helps show where Corinne Hanotin may publish in the future.

Co-authorship network of co-authors of Corinne Hanotin

This figure shows the co-authorship network connecting the top 25 collaborators of Corinne Hanotin. A scholar is included among the top collaborators of Corinne Hanotin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Corinne Hanotin. Corinne Hanotin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Goodman, Shaun G., Gregory G. Schwartz, Deepak L. Bhatt, et al.. (2017). USE OF HIGH-INTENSITY STATIN THERAPY POST-ACUTE CORONARY SYNDROME IN THE ONGOING ODYSSEY OUTCOMES TRIAL OF ALIROCUMAB, A PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 MONOCLONAL ANTIBODY, VERSUS PLACEBO: INTERIM BASELINE DATA. Journal of the American College of Cardiology. 69(11). 153–153. 1 indexed citations

Tóth, Peter P., Sara Hamon, Steven R. Jones, et al.. (2016). Effect of alirocumab on specific lipoprotein non-high-density lipoprotein cholesterol and subfractions as measured by the vertical auto profile method: analysis of 3 randomized trials versus placebo. Lipids in Health and Disease. 15(1). 28–28. 39 indexed citations

Farnier, Michel, Peter J.H. Jones, Randall Severance, et al.. (2015). Efficacy and safety of adding alirocumab to rosuvastatin versus adding ezetimibe or doubling the rosuvastatin dose in high cardiovascular-risk patients: The ODYSSEY OPTIONS II randomized trial. Atherosclerosis. 244. 138–146. 160 indexed citations

Koren, Michael J., Eli M. Roth, James M. McKenney, et al.. (2015). Safety and efficacy of alirocumab 150 mg every 2 weeks, a fully human proprotein convertase subtilisin/kexin type 9 monoclonal antibody: A Phase II pooled analysis. Postgraduate Medicine. 127(2). 125–132. 15 indexed citations

Bays, Harold, Daniel Gaudet, Robert Weiss, et al.. (2015). Alirocumab as Add-On to Atorvastatin Versus Other Lipid Treatment Strategies: ODYSSEY OPTIONS I Randomized Trial. The Journal of Clinical Endocrinology & Metabolism. 100(8). 3140–3148. 182 indexed citations

Krauss, Ronald M., Poulabi Banerjee, Sara Hamon, et al.. (2014). Abstract 15525: Alirocumab, a Fully Human Monoclonal Antibody to Proprotein Convertase Subtilisin/kexin Type 9, and Its Effects on Lipoprotein Subfractions Determined by Ion Mobility. Circulation. 130. 1 indexed citations

Gaudet, Daniel, Dean J. Kereiakes, James M. McKenney, et al.. (2014). Effect of Alirocumab, a Monoclonal Proprotein Convertase Subtilisin/Kexin 9 Antibody, on Lipoprotein(a) Concentrations (a Pooled Analysis of 150 mg Every Two Weeks Dosing from Phase 2 Trials). The American Journal of Cardiology. 114(5). 711–715. 167 indexed citations

Koren, Michael J., Dean J. Kereiakes, Deborah A. Winegar, et al.. (2014). EFFECTS OF ALIROCUMAB, A FULLY HUMAN MONOCLONAL ANTIBODY TO PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9, ON LIPOPROTEIN PARTICLE CONCENTRATIONS DETERMINED BY NUCLEAR MAGNETIC RESONANCE: SUBSTUDY OF A RANDOMIZED DOUBLE-BLIND PHASE II CLINICAL TRIAL. Journal of the American College of Cardiology. 63(12). A1373–A1373. 2 indexed citations

Poitiers, Franck, et al.. (2014). RANDOMIZED, PARTIAL BLIND STUDY OF THE PHARMACODYNAMICS, PHARMACOKINETICS AND SAFETY OF MULTIPLE SUBCUTANEOUS DOSES OF ALIROCUMAB, A FULLY HUMAN MONOCLONAL ANTIBODY TO PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9, ADMINISTERED EVERY 4 WEEKS ALONE OR IN COMBINATION WITH EZETIMIBE OR FENOFIBRATE IN HEALTHY SUBJECTS. Journal of the American College of Cardiology. 63(12). A1375–A1375. 2 indexed citations

10.

Gaudet, Daniel, Dean J. Kereiakes, Eli M. Roth, et al.. (2012). Abstract 14725: Effect of SAR236553/REGN727 Fully Human Monoclonal Anti-Proprotein Convertase Subtilisin/Kexin Type 9 Antibody on Plasma Lipoprotein(a) Concentrations: Pooled Analysis from Three Phase 2 Studies (NCT:01266876; 01288469; 01288443). Circulation. 126. 2 indexed citations

11.

Roth, Eli M., James McKenney, Corinne Hanotin, Gaëlle Asset, & Evan A. Stein. (2012). THE EFFECTS OF CO-ADMINISTERING A MONOCLONAL ANTIBODY TO PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 SERINE PROTEASE, REGN727/SAR236553, WITH 10 AND 80 MG ATORVASTATIN COMPARED TO 80 MG ATORVASTATIN ALONE IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA (NCT: 01288469). Journal of the American College of Cardiology. 59(13). E1620–E1620. 1 indexed citations

12.

McKenney, James M., et al.. (2012). Safety and Efficacy of a Monoclonal Antibody to Proprotein Convertase Subtilisin/Kexin Type 9 Serine Protease, SAR236553/REGN727, in Patients With Primary Hypercholesterolemia Receiving Ongoing Stable Atorvastatin Therapy. Journal of the American College of Cardiology. 59(25). 2344–2353. 416 indexed citations breakdown →

13.

Roth, Eli M., James M. McKenney, Corinne Hanotin, Gaëlle Asset, & Evan A. Stein. (2012). Atorvastatin with or without an Antibody to PCSK9 in Primary Hypercholesterolemia. New England Journal of Medicine. 367(20). 1891–1900. 383 indexed citations breakdown →

14.

Gaal, Luc F. Van, André Scheen, Aila Rissanen, et al.. (2008). Long-term effect of CB1 blockade with rimonabant on cardiometabolic risk factors: two year results from the RIO-Europe Study †. European Heart Journal. 29(14). 1761–1771. 120 indexed citations

15.

Zannad, Faı̈ez, Bertrand Gille, Alain Grentzinger, et al.. (2002). Effects of sibutramine on ventricular dimensions and heart valves in obese patients during weight reduction. American Heart Journal. 144(3). 508–515. 54 indexed citations

16.

Chapelot, Didier, Corinne Marmonier, Florence Thomas, & Corinne Hanotin. (2000). Modalities of the food intake-reducing effect of sibutramine in humans. Physiology & Behavior. 68(3). 299–308. 32 indexed citations

17.

Apfelbaum, M, P Vague, Olivier Ziegler, et al.. (1999). Long-term maintenance of weight loss after a very-low-calorie diet: a randomized blinded trial of the efficacy and tolerability of sibutramine. The American Journal of Medicine. 106(2). 179–184. 263 indexed citations

18.

Hanotin, Corinne, Florence Thomas, Stephen P. Jones, E. Leutenegger, & Pierre Drouin. (1998). A Comparison of Sibutramine and Dexfenfluramine in the Treatment of Obesity. Obesity Research. 6(4). 285–291. 32 indexed citations

19.

Hanotin, Corinne, et al.. (1997). Efficacy and tolerability of sibutramine in obese patients: a dose-ranging study. International Journal of Obesity. 22(1). 32–38. 78 indexed citations

20.

Coste, Joël, Corinne Hanotin, & E. Leutenegger. (1995). [Prescription of non-steroidal anti-inflammatory agents and risk of iatrogenic adverse effects: a survey of 1072 French general practitioners].. PubMed. 50(3). 265–70. 8 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact